Interpace Biosciences Inc. Releases Preliminary 2024 Financials

Interpace Biosciences Inc., a health care provider and service company specializing in molecular diagnostic tests for gastrointestinal and endocrine cancers, has released its preliminary financial results for the full year and fourth quarter of 2024. The company, based in Parsippany, United States, is actively engaged in the health care sector, focusing on the development and commercialization of tests that detect genetic and molecular alterations.

The company’s stock is traded on the OTC Bulletin Board, and its recent financial performance has been marked by significant volatility. Over the past year, Interpace Biosciences’ stock price has seen a 52-week high of $3.54 USD and a low of $0.443 USD. The most recent close price was $0.68 USD, reflecting a substantial decline from its peak. This fluctuation underscores the complex financial landscape the company navigates, prompting a closer examination of its financial statements to identify the factors influencing its performance.

Interpace Biosciences Inc. was initially public through an IPO on May 20, 1998. As of the latest data, the company has a market capitalization of $3,220,000 USD and a price-to-earnings ratio of 0.74949. These figures provide a snapshot of the company’s financial standing and investor sentiment.

The company’s focus remains on advancing its molecular diagnostic capabilities, with the Interpace Diagnostics Group, Inc. website available at www.interpacediagnostics.com for further information. As Interpace Biosciences continues to navigate its financial challenges, stakeholders are keenly observing its strategic initiatives and market developments to gauge future performance.